Abstract:Abstract Background and Aims Alterations in gut microbiota in CKD patients have been linked to CKD progression, cachexia, and mortality. Gut dysbiosis is associated by modification of gut-microbiota-derived metabolites, including a decrease of short-chain fatty acids (SCFAs), an increase in gut-derived uremic toxins. Therefore, modulation of gut microbiota seems to be an attractive therapeutic approach. In silico studies led to the selection of bacterial species able to increase SCFAs production, improve gut function without having the enzymatic machinery for producing uremic toxins. The propose of this study is to indentify the impact of two different symbiotics containing the selected bacteria: 1) on both uremic toxins and SCFAs production using a Simulator of the Human Intestinal Microbial Ecosystem (SHIME) colonized with fresh feces from CKD or healthy controls (HC) and subsequently 2) on renal function, metabolic parameters, intestinal microbiota and gut-microbiota-derived metabolites in a mouse model of CKD (5/6 nephrectomy). Method 1) The SHIME® system manufactured by ProDigest (Ghent, Belgium) consists of systems comprising five double-wall biovessels simulating the stomach (ST), small intestine (SI), ascending colon (AC), transverse colon (TC), and descending colon (DC). The supernatant of the homogenized fecal slurry was inoculated into the AC (25 mL), TC (40 mL), and DC (30 mL), respectively. After fecal inoculation, SHIME system were fed in ST twice day with two different symbiotics (P1 or P2) for 10 days. After 7 days, we applied a diet amino acid (AA) challenge to all the groups. SCFAs and uremic toxins were quantified every day. 2) CKD mice received either P1 or P2 admix for 6 weeks. We measured food intake, body composition and renal function including renal fibrosis quantification. Plasma metabolomic and feces metagenomic analyses were performed. Results In vitro, the concentration of precursor of uremic toxins (indols and p-cresol) tended to be higher in DC colonized by feces from CKD patients and AA challenge increased uremic toxins production more significantly in CKD compared to HC. CKD microbiome showed a lower butyrate concentration at baseline and higher propionate and acetate production. Both P1 and P2 significantly limited uremic toxins production during AA challenge and increase SCFA production. In vivo, both symbiotics increased body weight (+14%) and food intake (+31%) compared to CKD mice on chow diet. Treatment did not impact lipid or glucose metabolism but fat accretion in epididymal was restored with P1. Both diets, but particularly P1, significantly reduced plasmatic urea, proteinuria, and kidney fibrosis. Symbiotics improved intestinal barrier with a greater expression of Occludin in the ileum. Metagenomic analyses of the gut microbiota indicated that the alfa-diversity was not different across groups while the beta-diversity was similar to the sham group if CKD mice were treated with symbiotics. Both symbiotics reduced significantly plasma levels of deleterious uremic toxins such as p-cresyl sulfate and indoxyl sulfate and symbiotics reduce fecal module of trypotophan degradation and other modules related to AA metabolism. Both diets increased fecal bacteria modules related to SCFAs production. Conclusion We have shown both in vitro and in vivo that a symbiotic association can reduce uremic toxins production and increase SCFA production by inducing a significant change in gut microbiota composition and function. These metabolic changes are associated with improved appetite, decreased uremic cachexia, and preserved renal function. This data needs be confirmed in a human clinical trial.

Synbiotic meal decreases uremic toxins in hemodialysis individuals: A placebo-controlled trial

Can curcumin supplementation reduce plasma levels of gut-derived uremic toxins in hemodialysis patients? A pilot randomized, double-blind, controlled study

A Symbiotic Meal Containing Extruded Sorghum and Probiotic (Bifidobacterium longum) Ameliorated Intestinal Health Markers in Individuals with Chronic Kidney Disease: A Secondary Analysis of a Subsample from a Previous Randomized and Controlled Clinical Trial

Synbiotic supplement for treatment of iron deficiency anaemia in haemodialysis patients: A randomized controlled trial

Could resistant starch supplementation improve inflammatory and oxidative stress biomarkers and uremic toxins levels in hemodialysis patients? A pilot randomized controlled trial.

Effects of fermentable high fiber diet supplementation on gut derived and conventional nitrogenous product in patients on maintenance hemodialysis: a randomized controlled trial

Effect of Synbiotic and Probiotic Supplementation on Serum Levels of Endothelial Cell Adhesion Molecules in Hemodialysis Patients: a Randomized Control Study

A possible link between polyunsaturated fatty acids and uremic toxins from the gut microbiota in hemodialysis patients: A hypothesis

Effects of Propolis Supplementation on Gut Microbiota and Uremic Toxin Profiles of Patients Undergoing Hemodialysis

The Efficacy of Prebiotic, Probiotic, and Synbiotic Supplementation in Modulating Gut-Derived Circulatory Particles Associated With Cardiovascular Disease in Individuals Receiving Dialysis: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Pea hull fiber supplementation does not modulate uremic metabolites in adults receiving hemodialysis: a randomized, double-blind, controlled trial

#3454 IMPACT OF SYMBIOTICS ON UREMIC TOXINS PRODUCTION, RENAL FUNCTION AND PEW SYNDROME IN SHIME AND CKD MICE MODELS

Effect of Dietary Inulin Supplementation on the Gut Microbiota Composition and Derived Metabolites of Individuals Undergoing Hemodialysis: A Pilot Study

Effects of High Amylose-Resistant Starch on Gut Microbiota and Uremic Toxin Levels in Patients With Stage-G3a-G4 Chronic Kidney Disease: A Randomized Trial

Inulin-type prebiotics reduce serum uric acid levels via gut microbiota modulation: a randomized, controlled crossover trial in peritoneal dialysis patients

A Vitamin E-Coated Polysulfone Membrane Reduces Serum Levels of Inflammatory Markers and Resistance to Erythropoietin-Stimulating Agents in Hemodialysis Patients: Results of a Randomized Cross-Over Multicenter Trial

Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects

Prebiotic Therapy with Inulin Associated with Low Protein Diet in Chronic Kidney Disease Patients: Evaluation of Nutritional, Cardiovascular and Psychocognitive Parameters

A Metagenomic Approach Does Not Elucidate Uremic Toxin Levels in Hemodialysis Patients.

Effects of a synbiotic product on blood antioxidative activity in subjects colonized with Helicobacter pylori

Short-Term Effects of a Therapeutic Diet on Biochemical Parameters in Hemodialysis Patients: A Randomized Crossover Trial